Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVRx’s Hypertension Implant Gains FDA Humanitarian Exemption

This article was originally published in The Gray Sheet

Executive Summary

The humanitarian device exemption for the Barostim neo legacy implantable electronic stimulator for hypertension is CVRx’ first commercial approval in the U.S. The Minneapolis company is also developing the Barostim therapy for treatment of heart failure

You may also be interested in...



CVRx: Pioneering Hypertension And Heart Failure Devices – Big Markets Take Big Funding

Starting as the first company with a device therapy for resistant hypertension, CVRx was soon competing with the renal denervation avalanche, along with trying to survive the economic collapse and a failed trial. Fortunately, the company had gotten its funding when the getting was good.

FDA Draft Guidance: How To Claim Humanitarian Device Status

Firms must document that humanitarian devices target a rare disease or condition, or a small subset of a common disease or condition, the draft explains.

CVRx: Can Devices Succeed Where Drugs Fail for High Blood Pressure?

With hypertension reaching pandemic proportions, more and more people are not successfully treated with the drugs that, until now, have been the only therapy. CVRx is the first to develop a device to provide patients with another option.

Topics

Related Companies

UsernamePublicRestriction

Register

MT033588

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel